Regular
NAV (05-Sep-24)
Returns (Since Inception)
Fund Size
₹8,648 Cr
Expense Ratio
1.82%
ISIN
INF204K01968
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
05 Jun 2004
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+50.10%
+54.79% (Cat Avg.)
3 Years
+18.17%
+18.09% (Cat Avg.)
5 Years
+29.66%
+29.12% (Cat Avg.)
10 Years
+16.36%
+15.75% (Cat Avg.)
Since Inception
+21.57%
— (Cat Avg.)
Equity | ₹8,423.23 Cr | 97.40% |
Others | ₹224.72 Cr | 2.60% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹1,194.34 Cr | 13.81% |
Lupin Ltd | Equity | ₹717.69 Cr | 8.30% |
Divi's Laboratories Ltd | Equity | ₹688.09 Cr | 7.96% |
Cipla Ltd | Equity | ₹513.02 Cr | 5.93% |
Dr Reddy's Laboratories Ltd | Equity | ₹492.22 Cr | 5.69% |
Apollo Hospitals Enterprise Ltd | Equity | ₹449.45 Cr | 5.20% |
Ajanta Pharma Ltd | Equity | ₹311.16 Cr | 3.60% |
Vijaya Diagnostic Centre Ltd | Equity | ₹276.26 Cr | 3.19% |
Gland Pharma Ltd | Equity | ₹275.78 Cr | 3.19% |
Aurobindo Pharma Ltd | Equity | ₹267.21 Cr | 3.09% |
Abbott India Ltd | Equity | ₹260.86 Cr | 3.02% |
Zydus Lifesciences Ltd | Equity | ₹253.85 Cr | 2.94% |
J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹249.85 Cr | 2.89% |
Triparty Repo | Cash - Repurchase Agreement | ₹230.69 Cr | 2.67% |
GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹228.61 Cr | 2.64% |
Mankind Pharma Ltd | Equity | ₹224.1 Cr | 2.59% |
Medplus Health Services Ltd | Equity | ₹209.02 Cr | 2.42% |
Pfizer Ltd | Equity | ₹193.02 Cr | 2.23% |
Narayana Hrudayalaya Ltd | Equity | ₹190.5 Cr | 2.20% |
Torrent Pharmaceuticals Ltd | Equity | ₹175.43 Cr | 2.03% |
Alkem Laboratories Ltd | Equity | ₹171.17 Cr | 1.98% |
Sanofi India Ltd | Equity | ₹156.79 Cr | 1.81% |
Fortis Healthcare Ltd | Equity | ₹154.5 Cr | 1.79% |
Thyrocare Technologies Ltd | Equity | ₹152.18 Cr | 1.76% |
Dr. Lal PathLabs Ltd | Equity | ₹111.07 Cr | 1.28% |
Syngene International Ltd | Equity | ₹97.72 Cr | 1.13% |
Orchid Pharma Ltd | Equity | ₹94.76 Cr | 1.10% |
Sanofi Consumer He | Equity | ₹80.61 Cr | 0.93% |
Indoco Remedies Ltd | Equity | ₹66.32 Cr | 0.77% |
Emcure Pharmaceuticals Ltd | Equity | ₹42.31 Cr | 0.49% |
AstraZeneca Pharma India Ltd | Equity | ₹42.21 Cr | 0.49% |
HealthCare Global Enterprises Ltd | Equity | ₹34.86 Cr | 0.40% |
Concord Biotech Ltd | Equity | ₹24.89 Cr | 0.29% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹23.38 Cr | 0.27% |
Net Current Assets | Cash | ₹-6.03 Cr | 0.07% |
Cash Margin - Ccil | Cash - Collateral | ₹0.05 Cr | 0.00% |
Large Cap Stocks
43.21%
Mid Cap Stocks
33.87%
Small Cap Stocks
18.90%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹8,342.62 Cr | 96.47% |
Standard Deviation
This fund
15.35%
Cat. avg.
15.96%
Lower the better
Sharpe Ratio
This fund
0.80
Cat. avg.
0.79
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.44
Higher the better
Since April 2005
Since May 2018
ISIN | INF204K01968 | Expense Ratio | 1.82% | Exit Load | 1.00% | Fund Size | ₹8,648 Cr | Age | 05 Jun 2004 | Lumpsum Minimum | ₹5,000 | Fund Status | Open Ended Investment Company | Benchmark | BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Dividends are added to the investor’s income and taxed according to their respective tax slabs. Additionally, if an investors dividend income exceeds INR 5,000 in a financial year, the fund house deducts a 10% Tax Deducted at Source (TDS) before distributing the dividend.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹14.97 Cr | 55.2% |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 1.0% | 1.0% | ₹791.70 Cr | 56.3% |
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹791.70 Cr | 54.1% |
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹31.78 Cr | 52.5% |
ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.4% | 1.0% | ₹183.39 Cr | 55.6% |
ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹183.39 Cr | 52.7% |
Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2560.38 Cr | 53.4% |
Mirae Asset Healthcare Fund Regular Growth Very High Risk | 1.9% | 1.0% | ₹2560.38 Cr | 51.2% |
Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹798.61 Cr | 52.8% |
Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹18.87 Cr | 51.4% |
Total AUM
₹5,54,956 Cr
Address
4th Floor, Tower A, Peninsula Business Park, Mumbai, 400 013
Your principal amount will be at Very High Risk